Limiting brain reperfusion injury by controlling mitochondrial function
Limiting brain reperfusion injury by controlling mitochondrial function
批准号:
9149032
负责人:
MAIK HUETTEMANN
金额:
$33.67万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-09-30 至 2019-06-30
关键词:
AffectAlgorithmsApoptosisAreaAstrocytesAttenuatedBlood flowBrainBrain InjuriesBrain IschemiaCalciumCardiopulmonary ResuscitationCause of DeathCell DeathCellular StressCerebrovascular DisordersCerebrumCessation of lifeDataElectron TransportEnzymesEventFree Radical FormationFree RadicalsGelGenerationsGoalsHeart ArrestHumanHyperactive behaviorImageIn VitroInflammationInterruptionIschemiaLeadLightMammalsMass Spectrum AnalysisMediatingMembrane PotentialsMetabolicMicrogliaMitochondriaMitochondrial ProteinsModelingMorbidity - disease rateNeurologicNeuronsOligodendrogliaOxidasesOxygenPatient-Focused OutcomesPharmaceutical PreparationsPhasePhosphorylationPhototherapyProcessProductionPropertyProtein DephosphorylationProton PumpRattusReactive Oxygen SpeciesReperfusion InjuryReperfusion TherapyResearchRespirationResuscitationSiteStressTestingTherapeuticTimeTissuescytochrome c oxidasedisabilityin vivoindexingirradiationmitochondrial membranemortalitynatural hypothermianeuroprotectionphosphoproteomicspreventpublic health relevancerestoration
中文摘要
英文摘要
DESCRIPTION (provided by applicant): Cerebrovascular disease, most notably brain ischemia, is a leading cause of death and long-term disability in the US. The current and only treatment is prompt restoration of blood flow to the ischemic tissue. However, a substantial portion of the damage caused by ischemia/reperfusion occurs during the reperfusion phase: as ischemic tissue is reoxygenated reactive oxygen species (ROS) are quickly generated, starting early during reflow. Reperfusion injury has proved difficult to treat pharmacologically, likely because effective drug concentrations have not built up sufficiently during the early phase of reperfusion. The mitochondrial electron transport chain (ETC) is a major site of ROS production during cellular stress due to ETC hyper-activation, which causes high mitochondrial membrane potentials (ΔΨm), which in turn trigger excessive ROS production. We thus propose that the ideal therapy should target the ETC non-invasively to prevent the generation of ROS from the onset of reflow. Accordingly, our overall goal in this application is to develop a new, non-invasive therapy to normalize mitochondrial hyperactivity during reflow. We will capitalize on the photoreceptive properties of cytochrome c oxidase (COX) for infrared light (IRL) to modulate mitochondrial activity, thereby attenuating the production of ROS and, as a result, limit ischemia/reperfusion injury in the brain. Cytochrome c oxidase is the primary cellular photo-acceptor of IRL and the terminal enzyme of the ETC. We have discovered four specific IRL wavelengths that partially inhibit COX (instead of activating COX, i.e., the current paradigm). We show that inhibitory IRL, applied at the time of reperfusion, provides profound neuroprotection. In this proposal, we will build on these compelling preliminary data and capitalize on the unique, multi-disciplinary expertise of our research team to: Identify the combinations and energies of our four IRL wavelengths that yield optimal inhibition of COX and mitochondria in vitro using isolated rat brain COX and mitochondria (Aim 1). Investigate the mechanism of IRL-mediated protection in support of our central hypothesis of IRL action during reperfusion: IRL → COX activity↓ → ΔΨm↓ → ROS↓ → viability↑, using real-time imaging of mitochondrial funtion in rat primary neural cells exposed to simulated ischemia-reperfusion (Aim 2). Develop IRL-mediated protection and identify the optimal temporal treatment paradigm using a rat model for global brain ischemia to maximize post-ischemic neuroprotection (Aim 3).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development and Testing of LUCID: A Therapeutic Device for Brain Injury Following Infant Cardiac Arrest
-
批准号:10515831
-
项目类别:
-
资助金额:$99.93万
-
财政年份:2022
-
负责人:MAIK HUETTEMANN
-
依托单位:
Development and Testing of LUCID: A Therapeutic Device for Brain Injury Following Infant Cardiac Arrest
-
批准号:10708811
-
项目类别:
-
资助金额:$98.66万
-
财政年份:2022
-
负责人:MAIK HUETTEMANN
-
依托单位:
Non-invasive mitochondrial modulation therapy for ischemic stroke
-
批准号:10352458
-
项目类别:
-
资助金额:$48.6万
-
财政年份:2021
-
负责人:MAIK HUETTEMANN
-
依托单位:
Non-invasive mitochondrial modulation therapy for ischemic stroke
-
批准号:10231915
-
项目类别:
-
资助金额:$49.15万
-
财政年份:2021
-
负责人:MAIK HUETTEMANN
-
依托单位:
Non-invasive mitochondrial modulation therapy for ischemic stroke
-
批准号:10583532
-
项目类别:
-
资助金额:$47.32万
-
财政年份:2021
-
负责人:MAIK HUETTEMANN
-
依托单位:
Infant NeuroLUX: A Novel Non-invasive Therapeutic Device for Neonatal Hypoxic Brain Injury
-
批准号:10001121
-
项目类别:
-
资助金额:$80.3万
-
财政年份:2019
-
负责人:MAIK HUETTEMANN
-
依托单位:
Infant NeuroLUX: A Novel Non-invasive Therapeutic Device for Neonatal Hypoxic Brain Injury
-
批准号:10017347
-
项目类别:
-
资助金额:$76.9万
-
财政年份:2019
-
负责人:MAIK HUETTEMANN
-
依托单位:
Control of Cell Respiration and Apoptosis by Phosphorylation of Cytochrome c
-
批准号:9982332
-
项目类别:
-
资助金额:$35.37万
-
财政年份:2017
-
负责人:MAIK HUETTEMANN
-
依托单位:
Control of Cell Respiration and Apoptosis by Phosphorylation of Cytochrome c
-
批准号:9236889
-
项目类别:
-
资助金额:$36.74万
-
财政年份:2017
-
负责人:MAIK HUETTEMANN
-
依托单位:
Regulation of Respiration and Apoptosis by Cytochrome c Phosphorylation.
-
批准号:8306157
-
项目类别:
-
资助金额:$28.59万
-
财政年份:2010
-
负责人:MAIK HUETTEMANN
-
依托单位:
Regulation of Respiration and Apoptosis by Cytochrome c Phosphorylation.
-
批准号:8718805
-
项目类别:
-
资助金额:$28.59万
-
财政年份:2010
-
负责人:MAIK HUETTEMANN
-
依托单位:
Regulation of Respiration and Apoptosis by Cytochrome c Phosphorylation.
-
批准号:7985610
-
项目类别:
-
资助金额:$28.88万
-
财政年份:2010
-
负责人:MAIK HUETTEMANN
-
依托单位:
Regulation of Respiration and Apoptosis by Cytochrome c Phosphorylation.
-
批准号:8499366
-
项目类别:
-
资助金额:$27.59万
-
财政年份:2010
-
负责人:MAIK HUETTEMANN
-
依托单位:
Regulation of Respiration and Apoptosis by Cytochrome c Phosphorylation.
-
批准号:8115206
-
项目类别:
-
资助金额:$28.59万
-
财政年份:2010
-
负责人:MAIK HUETTEMANN
-
依托单位:
海外基金